⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL729304 | 0.97 | — | — | |
| SCHEMBL2143745 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL731554 | 0.81 | ALDH1A1 (0.50) | — | |
| SCHEMBL6643858 | 0.79 | ALDH1A1 (0.56) | — | |
| Hydrochloric Acid SCHEMBL4575270 | 0.78 | ALDH1A1 (0.54) | — | |
| Hydrochloric Acid SCHEMBL4573460 | 0.78 | ALDH1A1 (0.54) | — | |
| SCHEMBL3820149 | 0.76 | TSHR (0.42) | — | |
| SCHEMBL9233585 | 0.75 | MAPT (0.42) | — | |
| SCHEMBL9512763 | 0.75 | CES2 (0.42) | — | |
| SCHEMBL4593050 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116673006-B | Preparation process and application of composite adsorption film material | 上海惊叹化学有限公司 | 2023-09-29 | — | — | CN | claimed |
| CN-116673006-A | Preparation process and application of composite adsorption film material | 上海惊叹化学有限公司 | 2023-09-01 | — | — | CN | claimed |
| CN-112209976-B | Decitabine intermediate compound V | 鲁南制药集团股份有限公司 | 2023-05-26 | — | — | CN | claimed |
| CN-112209976-A | Decitabine intermediate compound V | 鲁南制药集团股份有限公司 | 2021-01-12 | — | — | CN | claimed |
| EP-4743440-A1 | IONIZABLE LIPIDS | eTheRNA immunotherapies NV (BE) | 2026-05-20 | — | — | EP | disclosed |
| US-12605399-B2 | Compositions for CFTR MRNA therapy | TRANSLATE BIO, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-12576030-B2 | Compositions for delivery of codon-optimized mRNA | TRANSLATE BIO, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260060926-A1 | NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME | SAIL BIOMEDICINES INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250276972-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | GRITSCIENCE BIOPHARMACEUTICALS CO LTD (CN) | 2025-09-04 | — | — | US | disclosed |
| US-12404243-B2 | Inhibitors of the Wnt/beta-catenin pathway | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-09-02 | — | — | US | disclosed |
| EP-3749640-B1 | INHIBITORS OF THE WNT/BETA-CATENIN PATHWAY | UNIV CALIFORNIA (US) | 2025-07-16 | — | — | EP | disclosed |
| EP-4581012-A2 | NOVEL IONIZABLE LIPIDS AND LIPID NANOPARTICLES AND METHODS OF USING THE SAME | Sail Biomedicines, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-09-09 | — | — | US | disclosed |
| WO-2004037978-A2 | METHODS OF REDUCING THE ACTIVITY OF AND REDUCING THE CONCENTRATION OF A MUTANT KIT PROTEIN | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2004-05-06 | — | — | WO | disclosed |
| EP-1396488-A1 | FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2004-03-10 | — | — | EP | disclosed |
| US-6632958-B1 | An alkene (1) is added to cyclopentenone (2) under the action of an alkyl lithium and an organic copper reagent to form an adduct, said adduct is reacted with e.g. a carboxylic anhydride (4) to obtain a prostaglandin derivative, which is | MITSUBISHI PHARMA CORPORATION (JP) | 2003-10-14 | — | — | US | disclosed |
| US-6548515-B1 | Use as anticancer agents | LES LABORATORIES SERVIER (FR) | 2003-04-15 | — | — | US | disclosed |
| WO-2002036574-A1 | GELDANAMYCIN DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-05-10 | — | — | WO | disclosed |
| EP-1085012-A1 | PROCESS FOR PRODUCING PURIFIED PROSTAGLANDIN DERIVATIVE | Asahi Glass Co., Ltd. (JP) | 2001-03-21 | — | — | EP | disclosed |
| US-5777114-A | Spiro heterocycle-imidazo 1,2-a!indeno 1,2-e!pyrazine!-4'-ones, preparation thereof and drugs containing same | RHONE-POULENC RORER S.A. (FR) | 1998-07-07 | — | — | US | disclosed |